This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
Vivian Xie
12 Jun 2023

Novo Nordisk announces expansion of Hillerød API manufacturing facility

Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.

Novo Nordisk have announced on June 12, 2023 that they are to invest DKK 15.9 billion kr. for the expansion of their API manufacturing facility in Denmark for products that treat serious chronic diseases, such as diabetes.

The current production facility, located in Hillerød, Denmark, will benefit from the investment with increased production capacity and enable the Danish pharmaceutical company to meet market demands in the future regarding drug products for chronic diseases. The facility will particularly develop Novo Nordisk’s ability to develop a clinical late-phase product portfolio in the future. 

An additional 65,000 m2 will be added to design a multi-product facility and house state-of-the-art technology to ensure flexibility in accommodating new processes. The new facility will be geared towards delivering high-quality drug products compliant with environmental sustainability regulations through the use of compact and optimal process flow that reduce the consumption of water and energy. Construction has already begun, with the facility to start producing APIs by 2029, creating 340 new jobs within the region. 

Henrik Wulff, Executive VP of Product Supply, Quality & IT at Novo Nordisk, highlighted the importance of the investment and the healthcare opportunities that can be provided with the right infrastructure: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” he commented. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.” 

Source: Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark [Accessed June 12, 2023] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166116  

Vivian Xie
Editor - Custom Content

Related News